Glenmark Pharmaceuticals Limited, a research-led, global pharmaceutical company, has launched in India the first triple-drug fixed-dose combination (FDC) of the widelyused Teneligliptin with Dapagliflozin and Metformin. This FDC has been launched under the brand name Zita DM, and it contains the DPP4 inhibitor, Teneligliptin (20mg), the SGLT2 inhibitor, Dapagliflozin, (10mg), and Metformin SR (500mg/1000mg) in a fixed dose. It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes.

On the occasion of the launch, Alok Malik, President & Business Head ‐ India Formulations, Glenmark Pharma stated, "India has the second-largest diabetic population in the world and Type 2 diabetic patients here often face issues of uncontrolled Hemoglobin A1C (HbA1Ci), beta cell dysfunction, which impairs insulin secretion, along with other co-morbidities like weight gain. Diabetes management, hence, becomes difficult for these patients and a challenge for healthcare providers. Being a leaderin treating diabetes, we are proud to introduce Zita DM, a novel and affordable anti-diabetic drug, which helps improve the glycemic control among adult patients with high HbA1c and other co-morbidities; while also reducing major renal and cardiac adverse events. With this robust profile, we are positive Zita DM will facilitate patient adherence to chronic diabetes treatments."

Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually, in India. With the launch of Zita DM, Zita the most comprehensive gliptin range now holds promise of helping Type 2 diabetic patients at every stage of their treatment.

According to IQVIA sales data for the 12‐month period ending August 2023 (MAT August 2023), the market for oral anti‐diabetic drugs in India is estimated to be INR 12,522 crores, with an annual growth of 6.5% against the corresponding period last year (MAT August 2022). As per the ICMR-INDIAB study conducted between 17th October 2008 and 17th December 2020, the overall weighted prevalence of diabetes was 11.4%.

Glenmark has a strong legacy of bringing in new, effective, and affordable treatment options for diabetic patients, especially with uncontrolled Type 2 diabetes. In 2015, Glenmark was the first to launch the DPP4 inhibitor, Teneligliptin (Zita Plus and Ziten), followed by a FDC of Teneligliptin + Metformin (Zita-Met Plus and ZitenM).

Glenmark later introduced Remogliflozin (Remo and Remozen), a novel SGLT-2 inhibitor in 2019; and subsequently, its combinations (Remo-V, Remozen-V, Remo MV, and Remozen MV).

Glenmark followed that up with the launch of Sitagliptin (Sitazit) and its FDCs in 2022. Then came Lobeglitazone (LOBG) and additional FDCs of Teneligliptin, including its combinations with Pioglitazone (Zita Pio), Pioglitazone + Metformin (Zita-PioMet), and Dapagliflozin (Zita-D).